All In Biotech

Drug Trial Radar · NCT07569042

A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Who Completed Study NBM-BMX-003 (the Parent Study)

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Sep 30, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long-term safety and efficacy of NBM-BMX administered in combination with TMZ.

Conditions

  • Malignant Neoplasm of Brain

Interventions

  • NBM-BMX CapsuleDrug

    Each capsule contains 100 mg of the active ingredient.

  • TemozolomideDrug

    Temodal will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, types, severity, and relationship to NBM-BMX of adverse events (AEs)Time frame: Through study completion, an average of 1 year.
  2. Progression-free survival (PFS) and overall survival (OS)Time frame: Through study completion, an average of 1 year.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Not yet recruiting

  • Linkou Chang-Gung Memorial Hospital

    Taoyuan City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.